European Journal of Haematology

Article	Citations
Issue Information	115
	71
The association of age and adverse events of PEG‐asparaginase in a pediatric tertiary care hospital; a retrospective review	44
	43
Clinical efficacy of simoctocog alfa versus extended half‐life recombinant FVIII concentrates in hemophilia A patients undergoing personalized prophylaxis using a matching‐adjusted indirect	41
Issue Information	33
Issue Information	32
Comparison of Hetrombopag and Eltrombopag Added to First‐Line Immunosuppressive Therapy in Severe Aplastic Anemia	30
Plasma microbial cell‐free DNA following chimeric antigen receptor T cell therapy in pediatric patients with relapsed/refractory leukemia	29
Myeloproliferative Neoplasms and Dementia Risk: A Population‐Based Cohort Study	28
Augmenter of liver regeneration promotes drug resistance of acute lymphoblastic leukemia through the alteration of mitochondrial functions and the inhibition of the mitochondrial apoptosis pathway	27
Platelet transfusions and predictors of bleeding in patients with myelodysplastic syndromes	25
Desensitization protocol to lenalidomide: An effective and safe treatment modality for delayed hypersensitivity‐induced rash in patients with multiple myeloma	24
Nationwide study of eculizumab in paroxysmal nocturnal hemoglobinuria: Evaluation of treatment indications and outcomes	23
Long‐term effectiveness of eculizumab: Data from the International PNH Registry	22
Utilization and outcome disparities in allogeneic hematopoietic stem cell transplant in the United States	22
Application of thromboelastography to predict the severity of bleeding after chimeric antigen receptor (CAR)‐T cell therapy in patients with hematological malignancy	21
Flow cytometry for comprehensive assessment of platelet functional activity in response to ADP stimulation	21
Effects of tertiary palliative care on the pattern of end‐of‐life care in patients with hematologic malignancies in Korea	20
Individualized busulfan dosing improves outcomes compared to fixed‐dose administration in pre‐transplant minimal residual disease‐positive acute myeloid leukemia patients with intermediate‐risk underg	18
Impact of Gut Microbiota and Inflammatory Cytokines on Immune Thrombocytopenia	18
Enhancing thalassemia gene carrier identification in non‐anemic populations using artificial intelligence erythrocyte morphology analysis and machine learning	18
Pixantrone as a bridge to CAR‐T treatment in high‐grade transformation of follicular lymphoma	18
Prophylaxis with recombinant von Willebrand factor in patients with type 3 von Willebrand disease: Results of a post hoc analysis from a phase 3 trial	17
Post‐transplant maintenance therapy in patients with FLT3‐mutated acute myeloid leukemia: Real‐world treatment patterns and outcomes	17

A low‐dose rituximab regimen for first‐line treatment of acquired haemophilia A	17
BAY 81‐8973 Demonstrates Long‐Term Safety and Efficacy in Children With Severe Haemophilia A: Results From the LEOPOLD Kids Extension Study	17
Antiemetic prophylaxis regimens in haematologic malignancies patients undergoing a hematopoietic stem cell transplantation. Which is the best standard of care? A systematic review	16
Health‐related quality of life in patients with β‐thalassemia: Data from the phase 3 BELIEVE trial of luspatercept	16
Home‐Based Daratumumab in Patients With Multiple Myeloma	16
Issue Information	16
Transfusion requirements and complication rate in β‐thalassemia intermedia due to heterozygous β‐globin gene mutation and triplicated α‐globin genes	15
Are we ready for personalizedCAR‐Ttherapy?	15
Pharmacokinetics and pharmacodynamics of an oral formulation of decitabine and tetrahydrouridine	15
Prognostic impact of translocation t(11;14) and of other cytogenetic abnormalities in patients with AL amyloidosis in the era of contemporary therapies	15
Efficacy of COVID‐19 vaccination in adult patients with sickle cell disease during the Omicron wave in France	14
HyperCVAD versus pegaspargase‐containing regimens for Hispanic adults with newly diagnosed B‐cell acute lymphoblastic leukemia	14
Predicting primary treatment failure using interim FDG‐PET scanning in diffuse large B‐cell lymphoma	13
Bortezomib‐based therapy for newly diagnosed multiple myeloma patients ineligible for autologous stem cell transplantation: Czech Registry Data	13
Intracranial hemorrhage in newly diagnosed non‐promyelocytic acute myeloid leukemia patients admitted for intensive induction chemotherapy	13
Soluble MIC‐A, IPI, and response to treatment strongly predict survival in patients with germinal center diffuse large B cell lymphoma	13
Relationship between hemoglobin, hemolysis, and transcranial Doppler velocities in children with sickle cell disease: Results from a long‐term natural history study in Italy in the era of multimodal t	12
	12
Ruxolitinib in patients with polycythemia vera resistant and/or intolerant to hydroxyurea: European observational study	12
Isatuximab, Carfilzomib, and Dexamethasone Combined With Late Autologous Stem Cell Transplantation: A Synergistic Strategy for First Relapse Multiple Myeloma	12
Venous thromboembolism prophylaxis in hospitalized sickle cell disease and sickle cell trait patients	12
Mutational profile, outcomes, and impact of allogeneic hematopoietic stem cell transplantation in adult patients with acute myeloid leukemia and inconclusive cytogenetic analysis	11
Persistent decreased bone marrow CD3+CD56+ T lymphocytes are inversely associated with mature granulocytes in myelodysplastic syndromes	11
Sequencing and combination of currentsmall‐moleculeinhibitors for chronic lymphocytic leukemia: Where is the evidence?	11
	11
Outcomes of COVID‐19 hospitalizations in patients with sickle cell disease: A nationwide analysis	11
Hematological and genetic profiles of persons with co‐inherited heterozygous β‐thalassemia and supernumerary α‐globin genes	11
BCR::ABL1 kinase domain mutation testing and clinical outcome in a nationwide chronic myeloid leukemia patient population	11
A post hoc analysis of PROTECT VIII Kids assessing long‐term efficacy and safety of damoctocog alfa pegol in adolescents with severe haemophilia A	10
Issue Information	10
Long‐term remission in a patient with relapsed Richter's transformation treated with CD19‐directed chimeric antigen‐receptor T‐cells after allogeneic stem cell transplantation	10
Assessment of joint bleeding and target joints in patients with severe or moderately severe hemophilia B (factor IX ≤2%) receiving prophylaxis with rIX‐FP in the PROLONG‐9FP clinical trial program	10
Adherence and Quality of Life in Adult Patients With Haemophilia A, Haemophilia B and Von Willebrand Disease: A National Cross‐Sectional Survey	10
Estrogen‐based hormonal therapy and the risk of thrombosis in COVID‐19 patients	10
Issue Information	10
Intensive salvage chemotherapy with VDTPACE or mCBAD followed by hematopoietic stem‐cell support for refractory/relapsed multiple myeloma	10
Platelet kinetics in patients with chronic immune thrombocytopaenia treated with thrombopoietin receptor agonists	9
Clinicopathological Prognostic Model for Survival in Adult Patients With Secondary Hemophagocytic Lymphohistiocytosis	9
Retracted: Bevacizumab synergises with the BCL 2 inhibitor venetoclax to effectively treat B‐cell non‐Hodgkin's lymphoma	9
End of treatment FDG‐PET in primary mediastinal B‐cell lymphoma treated with R‐chemotherapy: Prognostic indicator and implications for consolidation radiotherapy	9
The incidence, complications, and treatment of iron deficiency in pregnancy	9
Impact of Conditioning Intensity on Survival in Adult Patients (< 65 Years) With Acute Myeloid Leukemia Receiving Antithymocyte Globulin and Post‐Transplantation Cyclophosphamide Based GVHD	9
Secondary Malignancies After Autologous Stem Cell Transplantations in Patients With Malignant Lymphoma and Multiple Myeloma	9
Repeated immunosuppressive rabbit antithymocyte globulin therapy for adult patients with relapsed or refractory aplastic anemia	9
	9
Relationships between T‐lymphocytes and physical function in adults with chronic lymphocytic leukemia: Results from the HEALTH4CLL pilot study	9
Three cases of late‐onset post CAR‐T therapy isolated CNS relapse in R/R large B‐cell lymphoma	8
Impact of prior treatment on selinexor, bortezomib, dexamethasone outcomes in patients with relapsed/refractory multiple myeloma: Extended follow‐up subgroup analysis of the BOSTON trial	8
Treatment with temozolomide and ibrutinib in recurrent/refractory primary (PCNSL) and secondary CNS lymphoma (SCNSL)	8
	8

	8
Autologous stem cell transplantation in multiple myeloma patients over 70 years: A GIMEMA Lazio Working Group experience in a retrospective case–control study	8
Asciminib in Advanced‐Line Treatment of Chronic Myeloid Leukemia	8
Global prevalence of anemia among women of reproductive age, 2000–2019	8
Impact of infectious comorbidity and overall time of hospitalization in total outpatient management of acute myeloid leukemia patients following venetoclax and hypomethylating agents	8
Fecal microbiota transfer for refractory intestinal graft‐versus‐host disease — Experience from two German tertiary centers	8
A precision‐based exercise program for patients with multiple myeloma	8
Use of midostaurin in mixed phenotype acute leukemia with FLT3 mutation: A case series	8
Impact of newly diagnosed extramedullary myeloma on outcome after first autograft followed by maintenance: A CMWP‐EBMT study	8
Subclones with variants of uncertain clinical significance might contribute to ineffective hemopoiesis and leukemia predisposition	8
	8
	8
	8
Long‐term haematological response and maintained immunological function after laparoscopic subtotal splenectomy in patients with hereditary spherocytosis	8
Interferon gamma regulates a complex pro‐survival signal network in chronic lymphocytic leukemia	7
Healthcare resource utilization in patients with myeloproliferative neoplasms: A Danish nationwide matched cohort study	7
Survival and risk of vascular complications in myelofibrosis—A population‐based study from the Swedish MPN group	7
Comparison of outcomes between Hodgkin's lymphoma patients treated in and outside clinical trials: A study based on theEORTC‐Dutchlate effects cohort‐linked data	7
Chimeric antigen receptor T cells for acute myeloid leukemia	7
Outpatient consolidation chemotherapy with intermediate dose cytarabine has similar survival and relapses rates in acute myeloid leukemia as compared to high dose cytarabine: A single center analysis	7
ProGraME: A novel flow cytometry algorithm for the diagnosis of low‐risk myelodysplastic syndromes in patients with cytopenia	7
15‐color highly sensitive flow cytometry assay for post anti‐CD19 targeted therapy (anti‐CD19‐CAR‐T and blinatumomab) measurable residual disease assessment in B‐lymphoblastic le	7
Phenotype of BTK‐lacking myeloid cells during prolonged COVID‐19 and upon convalescent plasma	7
Development and validation of the sickle cell stress scale‐adult	7
Combinatorial treatment for unresectable unicentric Castleman disease	7
Anti‐thymocyte Globulin and Post‐Transplant Cyclophosphamide do not abrogate the inferior outcome risk conferred by human leukocyte antigen‐A and ‐B mismatched donors	7
Droplet digital PCR for sensitive relapse detection in acute myeloid leukaemia patients transplanted by reduced intensity conditioning	7
Fetal Hemoglobin Decrease During Voxelotor Treatment	7
	7
Clinical outcomes of patients referred for asymptomatic neutropenia: A focus on racial disparities in hematology	7
Risk factors for hemorrhagic cystitis after allogeneic hematopoietic stem cell transplantation in a letermovir‐exposed CMV‐free population receiving PTCy	7
Health economic evidence for the use of molecular biomarker tests in hematological malignancies: A systematic review	7
Hematopoietic cell transplantation for telomere biology diseases: A retrospective single‐center cohort study	7
Clinical Management of Persistent Hypereosinophilia	7
Musculoskeletal Symptoms and Misdiagnoses in Children With Acute Myeloid Leukaemia: A Nationwide Cohort Study	7
Conditioning with melphalan 200 mg/m2 and subsequent ASCT improves progression‐free and overall survival in elderly myeloma patients compared to standard of care	6
Real‐world utility of early measurable residual disease assessments by multi‐parametric flow cytometry in adult patients with B‐lymphoblastic leukemia receiving Hyper‐CVAD induction chemoth	6
Effect of pre‐transplant JAK1/2 inhibitors and CD34 dose on transplant outcomes in myelofibrosis	6
Exercise in newly diagnosed patients with multiple myeloma: A randomized controlled trial of effects on physical function, physical activity, lean body mass, bone mineral density, pain, and quality of	6
Haematology Outcomes Network in Europe (HONEUR)—A collaborative, interdisciplinary platform to harness the potential of real‐world data in hematology	6
Bone marrow expression of CD68/CD163 macrophages, IL‐17 and FOXP3 cells in aplastic anemia and their relation to prognosis	6
Busulfan and cyclophosphamide‐based conditioning regimen still holds the promise of being a safe and efficacious regimen for allogeneic transplantation in patients with transfusion‐dependent thalassem	6
The applicability of the central line‐associated bloodstream infection (CLABSI) criteria for the evaluation of bacteremia episodes in pediatric oncology patients	6
Outcomes in Kaposi's sarcoma‐associated herpesvirus ‐associated primary effusion lymphoma and multicentric Castleman's disease in patients with human immunodeficiency virus (	6
Relevance, Risks, and Benefits of Early‐Phases Clinical Trials Participations for Patients With Hematological Malignancies From 2008 to 2023	6
Implementation of International Prognostic Index with flow cytometry immunophenotyping for better risk stratification of chronic lymphocytic leukemia	6
Treatment of Refractory Monoclonal Immunoglobulin Deposition Disease With BCMA Bispecific Antibody	6
The net clinical benefit of targeted agents in the upfront treatment of elderly/unfit chronic lymphocytic leukemia patients: Results of network meta‐analysis	6
Clinical characteristics of Australian treatment‐naïve patients with classical Hodgkin lymphoma from the lymphoma and related diseases registry	6
Featured Cover	6
Issue Information	6
Variability of treatment modalities and intensity in patients with severe haemophilia A on prophylaxis: Results from the Italian national registry	6
Response rates of extra‐nodal diffuse large B cell lymphoma to anti‐CD19‐CAR T cells: A real word retrospective multicenter study	6
Venetoclax in the Treatment of Multiple Myeloma: A Retrospective Analysis of 79 Patients	6
Re‐evaluation of rituximab therapy for idiopathic Castleman disease: Retrospective study from single‐center experience	6
Long‐term outcome in patients with follicular lymphoma following high‐dose therapy and autologous stem cell transplantation	6
Pattern of use and clinical outcomes with rIX‐FP in pediatric/adolescent patients with haemophilia B in Italy: Results from IDEAL real‐world study	6
	6
Issue Information	6
Full or intensity‐reduced high‐dose melphalan and single or double autologous stem cell transplant with or without bortezomib consolidation in patients with newly diagnosed multiple myeloma	6
Efficacy and safety of PD‐1 monoclonal antibody plus rituximab in relapsed/refractory diffuse large B cell lymphoma patients	6
The role of oral iron in the treatment of adults with iron deficiency	6
Efficacy of conventional‐dose cytarabine, idarubicin and thioguanine versus intermediate‐dose cytarabine and idarubicin in the induction treatment of acute myeloid leukemia: Long‐term results of the p	6
Trends and in‐hospital cardiac complications in patients with atrial fibrillation undergoing allogeneic stem cell transplant: A National Inpatient Sample analysis (2002–2019)	6
	6
Intravenous anakinra for the treatment of haemophagocytic lymphohistiocytosis/macrophage activation syndrome: A systematic review	6
	6
Cardiovascular risk in chronic myeloid leukaemia: A multidisciplinary consensus on screening and management	6
Screening for multidrug‐resistant organisms in high‐risk hospitalized patients with hematologic diseases	6
JAK2V617F drives gut microbiota differences in patients with myeloproliferative neoplasms	6
Risk‐based and individualised management of bleeding and thrombotic events in adults with primary immune thrombocytopenia (ITP)	6
ABO Blood Type and Short‐Term Mortality in Patients With Infection‐Associated Disseminated Intravascular Coagulation	6
Venetoclax Combined With FLAG‐IDA in Refractory or Relapsed Acute Myeloid Leukemia	6
Resveratrol and tetrahydroisoquinoline effects on neutrophil sensitivity to NETosis formation in low‐risk essential thrombocythemia patients	5
The Mortality of Adults With Sickle Cell Disease at a Comprehensive Sickle Cell Center	5
Tandem bispecific CD123/CLL‐1 CAR‐T cells exhibit specific cytolytic effector functions against human acute myeloid leukaemia	5
Patient age and donor HLA matching can stratify allogeneic hematopoietic cell transplantation patients into prognostic groups	5
Insulin‐like growth factor‐1 and insulin‐like growth factor binding protein‐3: impact on early haematopoietic reconstitution following allogeneic haematopoietic stem cell transplantation	5
Appropriateness of inpatient intravenous iron therapy in a Swiss tertiary care hospital	5
Issue Information	5

A post hoc analysis of PROTECT VIII kids assessing long‐term efficacy and safety of damoctocog alfa pegol in adolescents with severe haemophilia A	5
Immunophenotyping for the Assessment of Asymptomatic Lymphocytosis: A Retrospective Analysis and National Survey	5
	5
Racial disparities in the incidence and survival outcomes in diffuse large B‐cell lymphoma in adolescents and young adults	5
Progressive multifocal leukoencephalopathy in the context of newer therapies in hematology and review of new treatment strategies	5
Cytogenetic and molecular characteristics and outcomes of adult patients with early T‐cell precursor acute lymphoblastic leukemia	5
Incidence of cardiovascular and bleeding events and reasons for discontinuation in patients with chronic lymphocytic leukemia treated with ibrutinib—A retrospective analysis on consecutive patients fr	5
Increased Non‐Relapse Mortality in Older People With Allogeneic Hematopoietic Stem Cell Transplantation Using Fludarabine and Myeloablative Dose of Busulfan‐Based Regimen	5
Infection epidemiology in relation to different therapy phases in patients with haematological malignancies receiving CAR T‐cell therapy	5
MCIR1: A patient‐derived mantle cell lymphoma line for discovering new treatments for ibrutinib resistance	5
Validation of the GATMO score in predicting non‐relapse mortality following hematopoietic cell transplant in multiple myeloma patients	5
The impact of hematology electronic consultations on the management of iron deficiency	5
Assessing the Burden of C5 Inhibitor Treatment in Patients with Paroxysmal Nocturnal Hemoglobinuria	5
Effectiveness of progressive moderate‐vigorous intensity elastic resistance training on quality of life and perceived functional abilities in people with hemophilia: Secondary analysis of a randomized	5
Outcome data from >10 000 multiple myeloma patients in the Danish and Swedish national registries	5
A prospective study of posttransplant cyclophosphamide for unrelated donor peripheral blood stem cell transplant with special attention to graft content and the impact of a higher γδ T cell dose	5
Comparison of telomere length in patients with bone marrow failure syndromes and healthy controls	5
Improved Outcomes of Myeloma Cast Nephropathy in Newly Diagnosed Multiple Myeloma With Modern Anti‐Myeloma Therapies	5
Changes in body mass index during treatment of childhood acute lymphoblastic leukemia with the Nordic ALL2008 protocol	5
Recombinant factor IX Fc for the treatment of hemophilia B	5
Cyclosporine plus eltrombopag in the treatment of aplastic anemia with or without antithymocyte immunoglobulin: A multicenter real‐world retrospective study	5
Risk of infection according to the gamma globulin level in the 100 days following allogeneic stem cell transplantations	5
Treatment of Critical Bleeds in Patients With Immune Thrombocytopenia: A Systematic Review	5
Unveiling the Genetic and Clinical Differences of Acute Myeloid Leukemia (AML) in Obese Patients	5
The current challenges faced by people with hemophilia B	5
Childhood autoimmune hemolytic anemia: A scoping review	5
Evaluation of soluble P‐selectin as a predictive biomarker in acute symptomatic pulmonary embolism: Insights from a prospective observational study	5
Treatment horizon in multiple myeloma	5
Effects of anti‐Xa activity monitoring on the outcome of high‐risk pregnancies treated with a prophylactic dose of low‐molecular‐weight heparin	4
Utilization of a surgical database to provide care and assess perioperative treatment and outcomes in patients with bleeding disorders	4
Management of infection prophylaxis in Dutch patients with myelodysplastic syndromes, a web‐based case vignette questionnaire: The MINDSET study	4
Correction to “Venetoclax‐Based Therapy for Relapsed or Refractory Acute Myeloid Leukaemia Following Intensive Induction Chemotherapy”	4
Pomalidomide, Bortezomib, and Dexamethasone Versus Bortezomib and Dexamethasone in Relapsed or Refractory Multiple Myeloma: Final Survival and Subgroup Analyses From the OPTIMISMM Trial	4
	4
A single‐day polychemotherapy regimen with proteasome inhibitor combinations for relapsed/refractory myeloma in the era of novel therapies	4
Issue Information	4
	4
The safety of Bruton's tyrosine kinase inhibitors in B‐cell malignancies: A systematic review	4
Cytokine expression in pediatric patients with immune thrombocytopenia (ITP) in different phases of disease	4
Clonal Evolution in 207 Cases of Refractory or Relapsed Acute Myeloid Leukemia	4
Health‐related quality of life in patients with steroid‐refractory acute graft‐versus‐host disease	4
Survival outcomes for patients with multiple myeloma in France: A retrospective cohort study using the Système National des Données de Santé national healthcare database	4
CLLAF SCORE—A New Risk Score for Predicting Atrial Fibrillation in Treatment‐Naive CLL Patients Initiating First‐ and Second‐Generation BTK Inhibitor Therapy	4
The impact of donor type on resource utilisation and costs in allogeneic haematopoietic stem cell transplantation in the Netherlands	4
Marked hyperferritinemia in critically ill cancer patients	4
Global reported impacts of COVID‐19 on lymphoma patients and the emerging clinical management approaches in response to the ongoing pandemic	4
Relationship between plasma rabbit anti‐thymocyte globulin concentration and immunosuppressive therapy response in patients with severe aplastic anemia	4
Further Reflections on 6‐MP Adherence and Habit Strength: The Impact of Dose Adjustment Complexity and Caregiver Burden	4
Pretransplant bone marrow cellularity and blood count recovery are not associated with relapse or survival risk following allogeneic stem cell transplant for AML in CR	4
	4
Tyrosine kinase inhibitors and tumor lysis syndrome in hematologic malignancies: A systemic review	4
Pain and functional disability amongst adults with moderate and severe haemophilia from the Irish personalised approach to the treatment of haemophilia (iPATH) study	4
Assessing Disability in Thalassaemia: A Position Statement by the Thalassaemia International Federation	4
Apheresis collection of mononuclear cells for chimeric‐antigen receptor therapies	4
Venetoclax‐based non‐intensive induction followed by allogenic stem‐cell transplantation in elderly acute myeloid leukemia patients with adverse cytogenetics	4
Azacitidine–venetoclax versus azacitidine salvage treatment for primary induction failure or first relapsed acute myeloid leukaemia patients	4
Prevalence of non‐adherence and non‐compliance during maintenance therapy in adults with acute lymphoblastic leukemia and their associations with survival	4
Venetoclax induces deep and durable minimal residual disease‐negative remission in high‐risk TP53 disrupted B prolymphocytic leukaemia	4
Epidemiology and clinical outcomes of light‐chain amyloidosis in Sweden: A nationwide population‐based study	4
Herpes zoster prophylaxis with low‐dose acyclovir in patients with malignant lymphoma and multiple myeloma treated with autologous stem cell transplantation	4
LP2, a stable lanthipeptide derived from cAng‐(1‐7), exerts myeloprotective action in mice	4
Venetoclax‐based salvage therapy for adult patients with relapsed/refractory acute lymphoblastic leukemia	4
A New Strategy for Adult T‐Cell Leukemia Treatment Targeting Glycogen Synthase Kinase‐3β	4
Nilotinib‐induced bone marrow CD34+/lin‐Ph+ cells early clearance in newly diagnosed CP‐Chronic Myeloid Leukemia: Final report of the PhilosoPhi34 study	4
Receiving four or fewer cycles of therapy predicts poor survival in newly diagnosed transplant‐ineligible patients with myeloma who are treated with bortezomib‐based induction	4
VEXAS syndrome: A review of bone marrow aspirate and biopsies reporting myeloid and erythroid precursor vacuolation	4
Neutrophil to lymphocyte ratio in myelofibrosis patients treated with ruxolitinib may predict prognosis and rate of discontinuation	4
	4
Adjusted comparison between elotuzumab and carfilzomib in combination with lenalidomide and dexamethasone as salvage therapy for multiple myeloma patients	4
Iron Deficiency in the Presence of Anemia and Inflammation—A Sex‐Specific Cross‐Sectional Study	4
	4
ORPHEE: A Real‐World Study on rIX‐FP Prophylaxis Use in Adolescent/Adult Patients With Hemophilia B	4
Treatment and clinical outcomes of patients with acute myeloid leukemia in Finland 2010–2020: A retrospective analysis of electronic health records	4
Bimodal expression of potential drug target CLL‐1 (CLEC12A) on CD34+ blasts of AML patients	4
Maternal and Fetal Outcomes of Aplastic Anemia During Pregnancy and Delivery: Systematic Review and Meta‐Analysis	4
Real‐World Evidence of Crizanlizumab Showing Reductions in Vaso‐Occlusive Crises and Opioid Usage in Sickle Cell Disease	4
Differences in patient‐reported outcomes (PROs) by disease severity in light chain (AL) amyloidosis	4
Prognosis of patients with acute lymphoblastic leukaemia relapsing after allogeneic stem cell transplantation	4
Retrospective study on pomalidomide‐PACE as a salvage regimen in aggressive relapsed and refractory multiple myeloma	4
Chronic myeloid leukemia (CML) in children and adolescents—Clinicopathological findings	4
Clonal haematopoiesis of indeterminate potential and impaired kidney function—A Danish general population study with 11 years follow‐up	4
Development of the Cold Agglutinin Disease Symptoms and Impact Questionnaire (CAD‐SIQ)	4
Biological Findings and Clinical Outcomes in Patients Treated With R‐CHOP Plus High‐Dose Methotrexate as First‐Line Therapy in Large B‐Cell Lymphoma With Testis Involvement	4
Hyper‐CVAD and Modified CALGB‐10403 Regimens in Adult Patients With Philadelphia‐Negative Acute Lymphoblastic Leukemia: A Comparative Study	4
Allogeneic hematopoetic stem cell transplant for patients with refractory T‐Cell lymphomas	4
Safety of Crovalimab Versus Eculizumab in Patients With Paroxysmal Nocturnal Haemoglobinuria (PNH): Pooled Results From the Phase 3 COMMODORE Studies	3
Safety of outpatient stem cell mobilization with low‐ or intermediate‐dose cyclophosphamide in newly diagnosed multiple myeloma patients	3
Issue Information	3
Circulating endothelial cells and endothelial progenitor cells as potential predictors of acute GVHD after allogeneic hematopoietic stem cell transplantation	3
	3
Issue Information	3
	3
Isatuximab plus pomalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma in real‐world: The retrospective IMAGE study	3
Results of the compassionate program of inotuzumab ozogamicin for adult patients with relapsed or refractory acute lymphoblastic leukemia in Spain	3
MDS/CMML from resource‐limited region: Characteristics and comparison to tertiary reference European center	3